Health and Healthcare

Amgen : AMGN

All Amgen Articles

701 Articles

Chris Lange | Sep 26, 2015 at 9:25 AM EDT

How the Top Biotechs Handled the Valuation Shock

24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a…

Chris Lange | Sep 25, 2015 at 8:05 AM EDT

Short Sellers Increase Bets in Major Biotech

The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks…

Chris Lange | Sep 16, 2015 at 1:20 PM EDT

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut…

Chris Lange | Sep 16, 2015 at 11:05 AM EDT

Meet the Newest Biotech Collaboration: Amgen and Xencor

Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas…

Chris Lange | Sep 11, 2015 at 8:05 AM EDT

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased…

Jon C. Ogg | Sep 8, 2015 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Amgen, Dow, Fitbit, Office Depot, SanDisk, Wells Fargo, Yum and Many More

Tuesday’s top analyst upgrades, downgrades and initiations include Amgen, Dow Chemical, Fitbit, Office Depot, SanDisk, Wells Fargo and Yum! Brands.

Chris Lange | Aug 28, 2015 at 10:25 AM EDT

How Amgen Can Disrupt the Market for Cholesterol Drugs

Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.

Chris Lange | Aug 26, 2015 at 8:55 AM EDT

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | Aug 12, 2015 at 8:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech…

Chris Lange | Aug 6, 2015 at 2:20 PM EDT

5 Big FDA Decisions Expected in August

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and…

Chris Lange | Aug 3, 2015 at 11:25 AM EDT

Independent Research Firm Sees Higher Upside in Amgen

According to Argus, second-quarter earnings, along with a strong pipeline and general outlook, have positioned Amgen to take the market…

Paul Ausick | Jul 30, 2015 at 4:26 PM EDT

Amgen Earnings Point to New 52-Week High

ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm…

Chris Lange | Jul 30, 2015 at 11:23 AM EDT

What to Expect from Amgen Earnings

ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates…

Chris Lange | Jul 27, 2015 at 7:57 AM EDT

Short Sellers Back Off Major Biotechs

ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of…

Jon C. Ogg | Jul 26, 2015 at 10:21 AM EDT

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings…

1 … 24 25 26 27 28 … 47

Amgen : AMGN

All Amgen Articles

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

Meet the Newest Biotech Collaboration: Amgen and Xencor

Short Sellers Increase Bets in Major Biotechs

Top Analyst Upgrades and Downgrades: Amgen, Dow, Fitbit, Office Depot, SanDisk, Wells Fargo, Yum and Many More

How Amgen Can Disrupt the Market for Cholesterol Drugs

Short Sellers Become More Focused in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

5 Big FDA Decisions Expected in August

Independent Research Firm Sees Higher Upside in Amgen

Amgen Earnings Point to New 52-Week High

What to Expect from Amgen Earnings

Short Sellers Back Off Major Biotechs

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Amgen : AMGN

All Amgen Articles

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

Meet the Newest Biotech Collaboration: Amgen and Xencor

Short Sellers Increase Bets in Major Biotechs

Top Analyst Upgrades and Downgrades: Amgen, Dow, Fitbit, Office Depot, SanDisk, Wells Fargo, Yum and Many More

How Amgen Can Disrupt the Market for Cholesterol Drugs

Short Sellers Become More Focused in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

5 Big FDA Decisions Expected in August

Independent Research Firm Sees Higher Upside in Amgen

Amgen Earnings Point to New 52-Week High

What to Expect from Amgen Earnings

Short Sellers Back Off Major Biotechs

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

Featured Reads

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase